Seattle Genetics, Inc. (
recently commenced a phase II study of Adcetris in combination
with the current standard of care in treatment-naive patients
with diffuse large B-cell lymphoma (DLBCL).
The open-label, phase II study will evaluate roughly 50
frontline high-risk DLBCL patients, who will receive Adcetris in
combination with Rituxan and standard chemotherapy (R-CHOP).
The primary endpoint is to evaluate the complete remission
rate and safety of the A+RCHOP regimen. Secondary endpoints
include objective response rate, progression-free survival and
This study will generate tolerability data as well as
antitumor activity data achieved by Adcetris plus the current
standard frontline regimen.
In Jun 2013, Seattle Genetics had presented data at the
International Conference on Malignant Lymphoma (ICML) from a
phase II study of Adcetrisin patients with relapsed B-cell
lymphomas. The study involved 44 patients including 25 DLBCL
patients who achieved an objective response rate of 44%.
Seattle Genetics' sole marketed antibody-drug conjugate (ADC)
product is Adcetris. Adcetris is used for the treatment of
patients with Hodgkin lymphoma (HL) after failure of autologous
stem cell transplant (ASCT) or after failure of at least two
prior multi-agent chemotherapy regimens in patients who are not
suitable for ASCT. Adcetris is also approved for the treatment of
systemic anaplastic large cell lymphoma after failure of at least
one multi-agent chemotherapy regimen.
ADCs have lately been attracting a lot of interest with major
companies entering into collaborations. Seattle Genetics has an
alliance with Genentech, a business wing of
Roche Holding AG
), for the development of ADCs.
Seattle Genetics carries a Zacks Rank #3 (Hold). Currently,
Questcor Pharmaceuticals Inc. (
Actelion Ltd. (
look well positioned with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
SEATTLE GENETIC (SGEN): Free Stock Analysis
To read this article on Zacks.com click here.